Ensysce Biosciences, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated $493,104 in revenue from federal grants during the third quarter, a substantial decrease from $3.4 million in the same period last year. For the nine months ending September 30, 2025, total revenue from grants was $3.2 million, down from $3.9 million in the prior year. The decline is attributed to the timing of research activities eligible for funding under the company's MPAR grant, which began in September 2024, and a decrease in funding from the OUD grant that ended in August 2024.
Operating expenses for the third quarter increased to $4.2 million, compared to $2.8 million in the same quarter of 2024. This rise was driven primarily by a $1.3 million increase in research and development expenses, which totaled $3 million for the quarter, reflecting heightened clinical and pre-clinical activities for the company's lead product candidates, PF614 and PF614-MPAR. General and administrative expenses also rose to $1.3 million from $1.1 million year-over-year. The net loss for the quarter was $3.7 million, a stark contrast to a net income of $661,769 in the same quarter of the previous year.
Ensysce's total assets decreased to $3.2 million as of September 30, 2025, down from $5.6 million at the end of 2024. The company's cash and cash equivalents also fell significantly to $1.7 million from $3.5 million. Current liabilities increased slightly to $2.3 million, while total stockholders' equity dropped to $874,714 from $3.4 million. The company has not generated any product revenue and continues to rely heavily on external funding, including federal grants and equity financing, to support its operations.
Strategically, Ensysce has been active in securing funding through various offerings. In April 2025, the company completed a warrant inducement that generated approximately $2.2 million in gross proceeds. Additionally, a registered direct offering in March 2025 raised about $1.1 million. However, the company acknowledges that it requires substantial additional funding to support ongoing operations and product development, particularly as it prepares for the Phase 3 clinical trial for PF614.
Looking ahead, Ensysce's management expressed uncertainty regarding its ability to continue as a going concern without raising additional capital. The company anticipates that its cash resources will only sustain operations into the late first quarter of 2026 unless further financing is secured. The ongoing development of its product candidates and the establishment of a commercial infrastructure will require significant investment, and the company remains focused on exploring various funding avenues to support its growth strategy.
About Ensysce Biosciences, Inc.
Ensysce Biosciences is a clinical-stage pharmaceutical company developing innovative opioid and pain management solutions. Its proprietary TAAP and MPAR platforms create abuse-resistant and overdose-protective prodrugs, aiming to reduce misuse, overdose, and addiction. The company focuses on safer opioid products for pain relief and opioid use disorder, targeting markets with high societal impact, leveraging novel molecular delivery technologies to improve safety and efficacy.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.